116 related articles for article (PubMed ID: 15701141)
1. Factor Xa inhibition.
Bramlage P; Pittrow D; Kirch W
Eur J Clin Invest; 2005 Mar; 35 Suppl 1():1-3. PubMed ID: 15701141
[No Abstract] [Full Text] [Related]
2. [Heparinemia (anti-factor Xa activity].
Emile C
Rev Infirm; 2007 Nov; (135):49-50. PubMed ID: 18159695
[No Abstract] [Full Text] [Related]
3. DU-176b, an oral, direct Factor Xa antagonist.
Hylek E
Curr Opin Investig Drugs; 2007 Sep; 8(9):778-83. PubMed ID: 17729190
[TBL] [Abstract][Full Text] [Related]
4. Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events.
Drouet L; Bal Dit Sollier C
Eur J Clin Invest; 2005 Mar; 35 Suppl 1():21-6. PubMed ID: 15701144
[TBL] [Abstract][Full Text] [Related]
5. [New antithrombotic principles approaching clinical use].
Bergqvist D
Lakartidningen; 2004 Feb; 101(8):646-7. PubMed ID: 15024937
[No Abstract] [Full Text] [Related]
6. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
7. Current concepts for the prevention of venous thromboembolism.
Bramlage P; Pittrow D; Kirch W
Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142
[TBL] [Abstract][Full Text] [Related]
8. New strategies for the treatment of acute venous thromboembolism.
Prandoni P; Lensing AW; Pesavento R
Semin Thromb Hemost; 2006 Nov; 32(8):787-92. PubMed ID: 17171591
[TBL] [Abstract][Full Text] [Related]
9. New anticoagulant drugs: a critical perspective.
Haas S
Curr Hematol Rep; 2005 Sep; 4(5):335-8. PubMed ID: 16131432
[No Abstract] [Full Text] [Related]
10. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options.
Agnelli G; Caprini JA
J Surg Oncol; 2007 Sep; 96(3):265-72. PubMed ID: 17474075
[TBL] [Abstract][Full Text] [Related]
11. Oral anticoagulants--the old and the new.
Ansell J
Dis Mon; 2005; 51(2-3):208-12. PubMed ID: 15900274
[No Abstract] [Full Text] [Related]
12. New anticoagulants--the path from discovery to clinical practice.
Lohrmann J; Becker RC
N Engl J Med; 2008 Jun; 358(26):2827-9. PubMed ID: 18579818
[No Abstract] [Full Text] [Related]
13. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles].
Alban S
Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163
[TBL] [Abstract][Full Text] [Related]
14. Clearing the way: treating venous thromboembolism and deep vein thrombosis.
Lambing A
Adv Nurse Pract; 2005 Jun; 13(6):24-30; quiz 31. PubMed ID: 15984353
[No Abstract] [Full Text] [Related]
15. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
16. From heparins to factor Xa inhibitors and beyond.
Alban S
Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
[TBL] [Abstract][Full Text] [Related]
17. New anticoagulants & clinical trials.
Haideri N; Patel H
Mo Med; 2009; 106(1):60-4. PubMed ID: 19245126
[TBL] [Abstract][Full Text] [Related]
18. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
19. Emerging anticoagulants for the treatment of venous thromboembolism.
Weitz JI
Thromb Haemost; 2006 Sep; 96(3):274-84. PubMed ID: 16953267
[TBL] [Abstract][Full Text] [Related]
20. Heparin therapy and monitoring: a role for the chromogenic antifactor Xa assay.
Rosén S; Casoni MC
Am Clin Lab; 2001 Aug; 20(7):35-8. PubMed ID: 11570272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
